<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811731</url>
  </required_header>
  <id_info>
    <org_study_id>144BE15006</org_study_id>
    <nct_id>NCT02811731</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B</brief_title>
  <official_title>A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan 16 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers (B)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and pharmacokinetics of CKD-330
      (fixed-dose combination of Candesartan 16 mg and Amlodipine 5 mg) with coadministration of
      the two separate drugs in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</time_frame>
    <description>A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</time_frame>
    <description>A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</time_frame>
    <description>A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</time_frame>
    <description>A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</time_frame>
    <description>A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</time_frame>
    <description>A. Candesartan: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 hr
B. Amlodipine: 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hr</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Candesartan and Amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-330</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-330 16/5mg - B, PO, 1days or 22days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-330 16/5mg - B</intervention_name>
    <arm_group_label>CKD-330</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan 16mg and Amlodipine 5mg</intervention_name>
    <arm_group_label>Candesartan and Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteer in the age between 19 and 45 years old.

          2. Body weight ≥ 55 kg and Body weight in the range of calculated IBW ±20%.

          3. Subjects without a hereditary problems and chronic disease.

          4. Subjects whose clinical laboratory test values are inside the accepted normal range.

          5. Understand the requirements of the study and voluntarily consent to participate in the
             study.

        Exclusion Criteria:

          1. Previous history or present of clinically significant hepatobiliary, nephrological,
             neurologic, respiratory, hemato-oncological, endocrine, urogenital, psychiatric,
             musculoskeletal, immune, otorhinolaryngological, cardiovascular system.

          2. History of gastrointestinal disease or gastrointestinal surgery to affect drug
             absorption.

          3. History of clinically significant allergies of amlodipine or candesartan or CCB or ARB
             or aspirin or antibiotic.

          4. Subjects with galactose intolerance.

          5. SBP ≥ 140 mmHg or&lt; 90 mmHg, DBP ≥ 95 mmHg or &lt; 60 mmHg, pulse ≥ 100 BPM.

          6. AST or ALT &gt; 2*ULN, total bilirubin &gt; 2*ULN

          7. Serum Creatinine &gt; ULN

          8. Previous history or present of drug abuse.

          9. Subjects treated metabolizing enzyme inducers or inhibitors such as barbitals within 1
             month prior to the first dosing.

         10. Subjects treated ethical drug or herbal medicine within 2 weeks, OTC or vitamin within
             1 week prior to the first dosing.

         11. Subjects treated IP within 2 months prior to the first dosing.

         12. Subjects with whole blood donation within 2 months or component blood donation within
             1 month or blood transfusion within 1 month prior to the first dosing.

         13. Alcohol &gt; 21 units/week or cannot stop drinking.

         14. Cigarette &gt; 10 cigarettes/day.

         15. Subjects with the plan dental treatment(extraction, orthodontic, nerve treatment) or
             any surgery(plastic surgery, eye surgery - LASIK, LASEK).

         16. Not eligible to participate for the study at the discretion of investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jang Hee Hong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

